Results 51 to 60 of about 12,408 (263)
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer [PDF]
BACKGROUND: Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several predictive factors of gefitinib sensitivity have been well described.
Hajime Asahina +13 more
core +2 more sources
Salvage Surgery Following Systemic Therapy in Initially Unresectable Non‐Small Cell Lung Cancer
Salvage pulmonary resection after systemic therapy for initially unresectable non‐small cell lung cancer achieved a high R0 rate with minimal morbidity and no perioperative mortality. Careful multidisciplinary selection facilitated a durable 5‐year survival rate of 75%.
Katsutoshi Seto +13 more
wiley +1 more source
The evidence on the effectiveness of management for malignant pleural effusion: a systematic review.
The aim of this study was to review systematically the available evidence on pleurodesis for malignant effusion, focusing on the choice of the agents, route of delivery and other strategies to improve outcomes. Four electronic databases (MEDLINE, EMBASE,
Browne, John +4 more
core +1 more source
Talc pleurodesis for malignant pleural effusion: efficacy and factors predicting recurrence [PDF]
Objectives: To identify potential factors predicting recurrence after talc pleurodesis for malignant pleural effusion. Methods: Retrospective study of two cohorts of consecutive patients undergoing surgery for malignant pleural effusion (T VATS/talc ...
Froeschle, P +3 more
core +1 more source
Tepotinib‐Induced Cholangitis in a Patient With Non‐Small Cell Lung Cancer: A Case Report
Here, we report the first case of tepotinib‐induced cholangitis. When using MET inhibitors for chemotherapy, attention should be paid not only to treatment effectiveness but also to possible hepatobiliary side effects. ABSTRACT Tepotinib, a mesenchymal epithelial transition factor (MET) tyrosine kinase inhibitor, is used to treat non‐small cell lung ...
Yoshimasa Hachisu +7 more
wiley +1 more source
Impact of systemic steroid treatment on talc pleurodesis: a report of six cases
Background Instillation of sterile graded talc in the pleural space is performed to prevent reaccumulation of malignant pleural effusion after drainage.
Soichiro Ishii +4 more
doaj +1 more source
Talcoma: A Diagnostic Challenge in Differential Diagnosis of Pleural Masses
Talcoma is a pleural mass which may develop as a rare complication following talc pleurodesis. Talc pleurodesis is performed to obliterate the pleural space to prevent recurrent pleural effusions or persistent pneumothoraces.
Iclal Ocak, Rohit Dewan
doaj +1 more source
Background: Malignant pleural effusion affects many patients with advanced cancer. When chemotherapy or radiotherapy fails to relieve malignant pleural effusion and related symptoms, drainage and pleurodesis can help. Although surgical talc pleurodesis
Changsung Han +3 more
doaj +1 more source
Background Malignant pleural effusions (MPE) mostly arises from metastases to the pleura from other sites. Management of malignant effusions aims to palliate dyspnea and prevent the reaccumulation of pleural fluid to improve patients’ quality of life ...
Gamal Agmy +3 more
doaj +1 more source
Abstract A 4‐year‐old female spayed mixed‐breed dog received enucleation surgery of the right eye in 2018 following the diagnosis of glaucoma. The patient was presented in 2021 for recurrent swelling of the right orbit. Ultrasound confirmed the presence of a cystic structure, and chemical ablation with 1% polidocanol (compounded, Stokes Pharmacy, Mt ...
Marissa R. Matthews +5 more
wiley +1 more source

